Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18614993 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | March 2024 | March 2025 | Abandon | 12 | 2 | 0 | No | No |
| 18090647 | PHARMACEUTICAL COMPOSITION | December 2022 | January 2025 | Abandon | 24 | 2 | 1 | Yes | No |
| 18077844 | SALVINORIN COMPOSITIONS | December 2022 | September 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17954557 | PHARMACEUTICAL COMPOSITIONS CONTAINING PARACETAMOL DERIVATIVES AND USE THEREOF | September 2022 | June 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17892620 | METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 35-64 YEARS | August 2022 | February 2025 | Abandon | 30 | 2 | 0 | No | No |
| 17857991 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | July 2022 | February 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17835051 | 18-MC FOR TREATING OBESITY | June 2022 | June 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17832566 | BVP8 PROTEIN FOR KILLING TETRANYCHID MITES AND USE THEREOF | June 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17831276 | USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE | June 2022 | June 2024 | Abandon | 24 | 2 | 0 | Yes | No |
| 17737218 | RAS INHIBITORS | May 2022 | September 2024 | Allow | 29 | 1 | 1 | No | No |
| 17614530 | COMPOSITIONS FOR DELIVERY OF LADOSTIGIL | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17595796 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | November 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17441082 | PESTICIDALLY ACTIVE AZOLE AMIDE COMPOUNDS | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17458031 | SYNTHESIS OF POZIOTINIB DERIVATIVE | August 2021 | May 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17429968 | SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALT | August 2021 | May 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17428396 | METHODS AND COMPOSITIONS FOR MODULATING BLOOD-BRAIN BARRIER | August 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17415279 | USE OF OLANZAPINE FOR TREATMENT OF PARP-INHIBITOR-INDUCED NAUSEA | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17325934 | HETEROCYCLIC COMPOUNDS | May 2021 | June 2025 | Allow | 49 | 1 | 1 | No | No |
| 17292663 | CRYSTALLINE FORMS OF A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND AND USE THEREOF AS P2X3 MODULATOR | May 2021 | June 2025 | Allow | 49 | 2 | 0 | No | No |
| 17291547 | FLAVONOID DELIVERY SYSTEM | May 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17286799 | TREATMENT OF NEUROLOGICAL DISEASE | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17281395 | INDOLE AHR INHIBITORS AND USES THEREOF | March 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17276920 | TLR8 AGONIST | March 2021 | April 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17276375 | PROPHYLACTIC AGENT FOR SPONTANEOUS CANCERS | March 2021 | March 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17187877 | LIQUID FORMULATION OF BIPHENYL-CONTAINING COMPOUND AND APPLICATION THEREOF | February 2021 | July 2025 | Allow | 52 | 4 | 0 | Yes | No |
| 17173069 | NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASES | February 2021 | February 2024 | Allow | 36 | 3 | 0 | No | No |
| 17265883 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | February 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17146327 | FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 | January 2021 | January 2024 | Allow | 37 | 1 | 1 | No | No |
| 17045392 | TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVES | October 2020 | November 2024 | Abandon | 49 | 0 | 1 | No | No |
| 16987092 | ACRIDINIUM ESTER-CONTAINING COMPOUNDS AND METHODS OF USING THE SAME FOR CHEMILUMINESCENCE-BASED ONE-COLOR SEQUENCING | August 2020 | March 2025 | Allow | 55 | 5 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ADLAM, CHANTAL PETA-GAYE works in Art Unit 1622 and has examined 29 patent applications in our dataset. With an allowance rate of 44.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner ADLAM, CHANTAL PETA-GAYE's allowance rate of 44.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ADLAM, CHANTAL PETA-GAYE receive 1.41 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ADLAM, CHANTAL PETA-GAYE is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +31.7% benefit to allowance rate for applications examined by ADLAM, CHANTAL PETA-GAYE. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.4% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.